BPC January 04 update

Biotech stocks close strongly for second consecutive day of 2017 while AEterna Zentaris (AEZS) delivers another Phase 3 failure

Price and Volume Movers

Biotech stocks rallied for the second consecutive trading day of 2017, a stark contrast to the first trading days of 2016.

Stocks closing the day over 10% outweighed those closing down 10% by 17:2 from the basket of approximately 400 companies covered by BioPharmCatalyst, most of which are mentioned below.

However, one company not to share in the strong start to 2017 is Aeterna Zentaris Inc. (NASDAQ: AEZS). It joined the list companies to report disappointing data this year when it announced after hours that its Phase 3 trial of Macrilen failed in the treatment of growth hormone deficiency in adults (AGHD). Shares of the company are currently down 40% to $2.20 in after-hours trading.

Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) surged by 64% to $3.40 on 43x average volume on the back of its release that it has launched an advertising campaign showing the benefits of its obesity drug, Contrave. The campaign aims to show how the brain plays an important role in weight loss.

CymaBay Therapeutics Inc (NASDAQ:CBAY), which announced after hours on Tuesday that it had formed a license agreement Kowa Pharmaceuticals America, Inc, saw its shares close up 21% to $2.30 on 92x average volume.

Agile Therapeutics Inc (NASDAQ:AGRX) shares closed off its lows at $2.63, a fall of 47% on 92x average volume. As noted yesterday,  the company released disappointing data from its Phase 3 SECURE trial of its contraceptive patch, Twirla.

Acura Pharmaceuticals, Inc (NASDAQ:ACUR) announced after hours on Tuesday that it is exploring various options regarding the structure of its company. These include;

“a possible sale of the company. Alternatives to a sale of the company include a capital raising transaction, a licensing transaction and a sale of certain assets.”

Shares of the company closed down 17% to $0.70 on 4x average volume.

Other major price movers (+10%):


Evoke Pharma Inc (NASDAQ:EVOK): $2.69; +30%; 14x average volume.

Merus NV (NASDAQ:MRUS): $25.90; +23%; 3x average volume.

ImmunoGen, Inc. (NASDAQ:IMGN): $2.49; +20%; 4x average volume.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): $0.71; +18%; 3x average volume.

Bellerophon Therapeutics Inc (NASDAQ:BLPH): $0.63; +16%; 9x average volume.

Eleven Biotherapeutics Inc (NASDAQ:EBIO): $2.31; +16%; 3x average volume.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP): $0.59; +16%; 2x average volume.

Achaogen Inc (NASDAQ:AKAO): $14.88; +14%; 2x average volume.

Adverum Biotechnologies Inc (NASDAQ:ADVM): $3.35; +14%.

Sangamo Biosciences, Inc.(NASDAQ:SGMO): $3.50; +13%.

Zosano Pharma Corp (NASDAQ:ZSAN): $0.87; +11%.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): $31.94; +11%; 3x average volume.

Global Blood Therapeutics Inc (NASDAQ:GBT): $15.85; +11%; 2x average volume.

Spark Therapeutics Inc (NASDAQ:ONCE): $59.49; +11%; 1.5x average volume.

Full pipeline updates:

Pipeline Database Updates

Drug Stage Catalyst

Macimorelin Acetate - Macrilen
Adult Growth Deficiency

PDUFA CRL issued November 2014. Phase 3 data released January 4, 2017 - trial failed. NDA resubmitted with new PDUFA date of December 30, 2017.

mGluR mutation positive ADHD

Phase 2/3 Phase 2/3 data released March 20, 2017 - primary endpoint not met. Subset of data released April 20, 2017 - to be presented April 21, 2017.


Phase 2b Phase 2b data released May 3, 2017 - primary endpoint met, secondary missed.

CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)

Phase 2 Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.

Prevention of chemotherapy-induced nausea and vomiting (CINV)

PDUFA PDUFA date November 12, 2017.